Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: Results from a retrospective observational study

Annals of the Rheumatic Diseases

Volumn 66, Issue 8, 2007, Pages 1059-1065

  Schoels, M ^b   Kapral, T ^a   Stamm, T ^a   Smolen, J S ^b   Aletaha, D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SULFASALAZINE; TREATMENT FAILURE;

EID: 34547170013     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.061820     Document Type: Article

References (44)

1. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational studies that disease-modifying antirheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002;41:1346-56.
2. Hurst S, Kalian MJ, Wolfe FJ, Fries JF, Albert DA. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. J Rheumatol 2002;29:1639-45.
3. Fries JF. Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol 1996;44:102-6.
4. Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613-19.
5. Yelin E, Wanke L. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-19.
6. Lajas C, Abasolo L, Bellajdel B, Hernandez-Garcia C, Carmona L, Vargas E, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Care Res 2006;49:64-71.
7. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-57.
8. Aletaha D, Eberl G, Nell V, Machold K, Smolen JS. Practical progress in realization of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis 2002;61:630-4.
9. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:179-85.
10. Nell V, Machold K, Eberl G, Stamm T, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906-14.
11. Lard LR, Visser H, Speyer I, van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
12. Van der Heide A, Jacobs J, Bijlsma J, Heurkens A, Van Booma-Frankfort C, Van der Veen M, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996;124:699-707.
13. Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003;21:209-10.
14. Grigor C, Porter D, Kincaid W, Vallance R, Lock P, McMahon AD, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
15. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology 2002;41:1367-74.
16. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: a 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
17. Tugwell P, Pincus T, Yocum D, et al. Combination with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;33:137-41.
18. Kremer J, Caldwell J, Cannon G, Genovese M, Crush JC, Bathon JM, et al. Combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: a double blind placebo-controlled study. Arthritis Rheuma 2000;43(Suppl 9):224.
19. Weinblatt ME, Kremer JM, Coblyn JS, Macer AL, Helfgott SM, Morell M, et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
20. Van den Borne BE, Landewe RB, Geoi HS, Rietveld JH, Zwinderman AH, Bruyn GA, et al. Combination therapy in recent rheumatoid arthritis: a randomised double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998;25:1493-8.
21. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy: fact or fiction? Arthritis Rheum 2005;52:2975-83.
22. Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594- 602.
23. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
24. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61.
25. Edwards JC, Szcezepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
26. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
27. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002;29:1631-8.
28. Aletaha D, Smolen JS. Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis. Arthritis Rheum 2002;47:181-8.
29. Kapral T, Stamm T, Machold KP, Montag K, Aletaha D, Smolen JS. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. Arthritis Res Ther 2006;8:R46.
30. Goekoop YP, Allaart CF, Breedveld FC, Dijkmans BA. Combination therapy in rheumatoid arthritis. Curr Opin Rheumatol 2001;13:177- 83.
31. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998;37:612-19.
32. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
33. Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003;62:944-51.
34. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum 1994;37:1487-91.
35. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
36. Smolen JS, Van der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
37. Breedveld FC, Weisman MH, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
38. De la Mata J, Blanco FJ, Gomez-Reino JJ. Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. Ann Rheum Dis 1995;54:881-5.
39. Wolfe FJ, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
40. Jansen G, van der Heijden J, Oerlemans R, Lems WF, Ifergan I, Scheper RJ, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004;50:2130-9.
41. Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel PL. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann Rhem Dis 2005;64:44-51.
42. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF, Van Zeben D, Kerstens PJ. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
43. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-32.
44. Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis 1999;58(Suppl 1):i82-5.